Pacira Pharmaceuticals, Inc. PCRX-Financial and Strategic SWOT Analysis Review

Pacira Pharmaceuticals, Inc. PCRX-Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH23991FSA
  • |
  • Pages: 45
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Pacira Pharmaceuticals, Inc. (PCRX)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Pacira Pharmaceuticals, Inc. (Pacira) is a specialty pharmaceutical company. It focuses on the discovery, development, manufacture and commercialization of novel pharmaceutical products. It develops products based on its proprietary DepoFoam drug delivery technology. The company's products are used by hospitals and ambulatory surgery centers. Pacira's lead product candidate is Exparel, a liposome injection of bupivacaine, an amide-type local anesthetic is indicated for infiltration into the surgical site to produce postsurgical analgesia for up to 72 hours. The company's subsidiaries include Pacira Pharmaceuticals International, Inc., (the US); and Pacira Ltd., (the UK). Pacira is headquartered in Parsippany, New Jersey, the US.

Pacira Pharmaceuticals, Inc. Key Recent Developments

Oct 27, 2015: Pacira Pharmaceuticals Reports Third Quarter 2015 Financial Results

Oct 20, 2015: Pacira Pharmaceuticals Announces the Promotion of James S. Scibetta to President

Aug 19, 2015: Pacira Pharmaceuticals Appoints James B. Jones, MD, PharmD, as Senior Vice President and Chief Medical Officer

Jul 30, 2015: Pacira Pharmaceuticals Reports Second Quarter 2015 Financial Results

Jul 14, 2015: Pacira Pharmaceuticals Appoints Scott Braunstein, MD, to Oversee Strategy and Corporate Development

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Section 1-About the Company 6

Pacira Pharmaceuticals, Inc.-Key Facts 6

Pacira Pharmaceuticals, Inc.-Key Employees 7

Pacira Pharmaceuticals, Inc.-Key Employee Biographies 8

Pacira Pharmaceuticals, Inc.-Major Products and Services 9

Pacira Pharmaceuticals, Inc.-Pharmaceutical Pipeline Products Data 10

Pacira Pharmaceuticals, Inc., Pipeline Products by Therapy Area 10

Pacira Pharmaceuticals, Inc., Pipeline Products by Development Phase 11

Pacira Pharmaceuticals, Inc.-History 13

Pacira Pharmaceuticals, Inc.-Locations And Subsidiaries 15

Head Office 15

Other Locations & Subsidiaries 15

Section 2-Company Analysis 16

Pacira Pharmaceuticals, Inc.-Business Description 16

Pacira Pharmaceuticals, Inc.-Corporate Strategy 17

Pacira Pharmaceuticals, Inc.-SWOT Analysis 18

SWOT Analysis-Overview 18

Pacira Pharmaceuticals, Inc.-Strengths 18

Strength-Lead Product-Exparel 18

Strength-Research and Development Activities 18

Strength-Strategic Partnerships and Agreements 18

Pacira Pharmaceuticals, Inc.-Weaknesses 19

Weakness-Declining Performance of DepoCyte 19

Pacira Pharmaceuticals, Inc.-Opportunities 20

Opportunity-Market Potential: Pain 20

Opportunity-Pipeline Products 20

Opportunity-Changing Demographics 20

Pacira Pharmaceuticals, Inc.-Threats 21

Threat-Stringent Government Regulations 21

Threat-Dependence on Third Parties 21

Threat-Competitive Environment 21

Pacira Pharmaceuticals, Inc.-Key Competitors 22

Section 3-Company Financial Ratios 23

Financial Ratios-Capital Market Ratios 23

Financial Ratios-Annual Ratios 24

Performance Chart 25

Financial Performance 25

Financial Ratios-Interim Ratios 26

Financial Ratios-Ratio Charts 27

Section 4-Company's Lifesciences Financial Deals and Alliances 28

Pacira Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 28

Pacira Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 29

Pacira Pharmaceuticals, Inc., Recent Deals Summary 30

Section 5-Company's Recent Developments 31

Oct 27, 2015: Pacira Pharmaceuticals Reports Third Quarter 2015 Financial Results 31

Oct 20, 2015: Pacira Pharmaceuticals Announces the Promotion of James S. Scibetta to President 34

Aug 19, 2015: Pacira Pharmaceuticals Appoints James B. Jones, MD, PharmD, as Senior Vice President and Chief Medical Officer 35

Jul 30, 2015: Pacira Pharmaceuticals Reports Second Quarter 2015 Financial Results 36

Jul 14, 2015: Pacira Pharmaceuticals Appoints Scott Braunstein, MD, to Oversee Strategy and Corporate Development 37

Apr 30, 2015: Pacira Pharmaceuticals Reports First Quarter EXPAREL Revenues of USD 56.0 Million and First Quarter 2015 Financial Results 38

Feb 24, 2015: Pacira Pharmaceuticals Reports 2014 Financial Results 39

Jan 08, 2015: Pacira Pharmaceuticals Reports Estimated Fourth Quarter Total Revenue of USD 61.8 Million and Estimated Full-Year Total Revenue of USD 197.7 Million 40

Section 6-Appendix 41

Methodology 41

Ratio Definitions 41

About GlobalData 45

Contact Us 45

Disclaimer 45

List of Figures

Pacira Pharmaceuticals, Inc., Pipeline Products by Therapy Area 10

Pacira Pharmaceuticals, Inc., Pipeline Products by Development Phase 11

Pacira Pharmaceuticals, Inc., Performance Chart (2011-2015) 25

Pacira Pharmaceuticals, Inc., Ratio Charts 27

Pacira Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 28

Pacira Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 29

List of Tables

Pacira Pharmaceuticals, Inc., Key Facts 6

Pacira Pharmaceuticals, Inc., Key Employees 7

Pacira Pharmaceuticals, Inc., Key Employee Biographies 8

Pacira Pharmaceuticals, Inc., Major Products and Services 9

Pacira Pharmaceuticals, Inc., Number of Pipeline Products by Therapy Area 10

Pacira Pharmaceuticals, Inc., Number of Pipeline Products by Development Stage 11

Pacira Pharmaceuticals, Inc., Pipeline Products By Therapy Area and Development Phase 12

Pacira Pharmaceuticals, Inc., History 13

Pacira Pharmaceuticals, Inc., Other Locations 15

Pacira Pharmaceuticals, Inc., Subsidiaries 15

Pacira Pharmaceuticals, Inc., Key Competitors 22

Pacira Pharmaceuticals, Inc., Ratios based on current share price 23

Pacira Pharmaceuticals, Inc., Annual Ratios 24

Pacira Pharmaceuticals, Inc., Interim Ratios 26

Pacira Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 28

Pacira Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 29

Pacira Pharmaceuticals, Inc., Recent Deals Summary 30

Currency Codes 41

Capital Market Ratios 41

Equity Ratios 42

Profitability Ratios 42

Cost Ratios 43

Liquidity Ratios 43

Leverage Ratios 44

Efficiency Ratios 44

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Akorn, Inc.

AcelRx Pharmaceuticals, Inc.

Napp Pharmaceuticals Limited

Jazz Pharmaceuticals, Inc.

Scilex Pharmaceuticals, Inc.

DURECT Corporation

Pacira Pharmaceuticals, Inc. , SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license

Single User License
USD 125 INR 8131
Site License
USD 250 INR 16263
Corporate User License
USD 375 INR 24394

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com